Core Insights - GeneDx Holdings Corp. reported a significant turnaround in Q2 2025 with adjusted diluted EPS of 50 cents, compared to a loss of 8 cents per share in the same period last year, exceeding estimates by 400% [1][8] - Total revenues for the quarter increased by 45.6% year over year to $102.7 million, surpassing the Zacks Consensus Estimate by 21.2% [2][9] - The company achieved a gross profit of $70.9 million, reflecting a 65.1% year-over-year increase, with gross margin expanding by 813 basis points to 69% [3][9] Revenue Performance - Exome and genome test revenues grew by 69% year over year, reaching $85.9 million [2][9] - The company crossed the $100 million revenue mark for the first time, marking a significant milestone [9] Expense and Profitability Metrics - Adjusted total operating expenses were $61.9 million, an increase of 15.7% year over year, leading to an operating profit of $9 million compared to an operating loss of $10.6 million in the previous year [4][9] - Selling and marketing expenses rose by 17.3% to $19.4 million, while general and administrative expenses increased by 5.3% to $27.4 million [3] Cash Position - At the end of Q2 2025, GeneDx had cash, cash equivalents, and marketable securities totaling $134.6 million, down from $159.2 million at the end of Q1 2025 [5] Future Outlook - The company raised its full-year 2025 sales guidance to a range of $400-$415 million from the previous $360-$375 million, with the Zacks Consensus Estimate currently at $371.3 million [6] - Adjusted net income for the year is expected to be positive, with earnings estimated at $1.13 per share [6] Strategic Developments - During the quarter, GeneDx advanced its growth strategy by acquiring Fabric Genomics, which supports a hybrid model for delivering genomic insights globally [10] - The company also expanded its commercial focus to include inborn errors of immunity as a new indication for its genetic testing [10]